Alzheimer’s disease (AD) is the most common cause of dementia worldwide, accounting for approximately 60–80% of all dementia cases, and its prevalence is rapidly increasing due to extended lifespans. Among the increasing number of genetic risk factors identified, the apolipoprotein E (ApoE) gene remains the strongest and most prevalent, impacting more than half of all AD cases. The ApoE gene has several variants, with ApoE ε4 being linked to an increased risk of Alzheimer’s.

New drug targets for early onset Alzheimer’s Disease, including aducanumab (Aduhelm), lecanemab (Leqembi), and donanemab that act to remove amyloid-beta plaques have been developed, and become available in the clinic. These drugs can slow Alzheimer’s progression and amyloid accumulation.

ApoE testing can sometimes guide your doctor in their treatment decision and monitoring of side effects. This involves a blood test. If you or your loved ones have early onset Alzheimer’s disease, please discuss with your doctor on whether ApoE testing is suitable for you.